Arthur Tzianabos compensation by year
Q32 Bio Summary Compensation Table · all 6 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Salary | $422,300 | $490,500 | $537,600 | $563,200 | $583,100 | $437,151 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $578,760 | $157,180 |
| Option awards | $1,815,320 | $3,562,722 | $4,217,097 | $0 | $2,116,074 | $603,575 |
| Non-equity incentive | $168,920 | $250,000 | $295,680 | $309,760 | $320,705 | $362,100 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $9,893 | $12,500 | $13,000 | $8,700 | $112,055 |
| Total | $2,406,540 | $4,313,115 | $5,062,877 | $885,960 | $3,607,339 | $1,672,061 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Q32 Bio Inc. DEF 14A filed April 28, 2023, accession 0000950170-23-015750, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Q32 Bio Inc. filed document, accession 0000950170-23-015750. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 58,000 | $73,080 | — |
| RSU | 28,140 | $35,456 | — |
| Option | 4,230 | — | $24.28 |
| Option | 96,959 | — | $19.92 |
| Option | 269,792 | — | $2.71 |
| Option | 132,292 | — | $13.78 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Q32 Bio Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
16 Form 4 lines since the FY2022 proxy (filed April 28, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-12 | Grant or award derivative | — | 10,826 | $0.00 | 10,826 |
| 2026-06-12 | Grant or award derivative | — | 9,810 | $0.00 | 9,810 |
| 2025-10-23 | Grant or award derivative | — | 53,521 | $0.00 | 53,521 |
| 2025-02-24 | Grant or award derivative | — | 12,767 | $0.00 | 12,767 |
| 2025-02-24 | Grant or award derivative | — | 25,674 | $0.00 | 25,674 |
| 2025-02-24 | Disposition to the issuer derivative | — | 12,767 | $0.00 | 0 |
| 2025-02-24 | Disposition to the issuer derivative | — | 25,674 | $0.00 | 0 |
| 2024-03-25 | Grant or award derivative | — | 12,767 | $0.00 | 12,767 |
The 8 most recent of 16 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Q32 Bio’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Arthur Tzianabos · this page | Chairman of the Board and former Chief Executive Officer | $1,672,061 |
| Albert Seymour | Chief Executive Officer | $1,197,487 |
| W. Bradford Smith | Chief Financial and Business Officer and Treasurer | $994,251 |
| Paul Alloway | Chief Legal Officer and Secretary | $868,639 |
Board service
Q32 Bio board · FY2024–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $45,000 | — | $118,237 | — | $163,237 |
| FY2024 | $51,427 | — | $164,607 | — | $216,034 |
Each year as the company reported it in Q32 Bio's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Q32 Bio pays directors a $40,000 cash retainer and $114,000 in Options. As stated in Q32 Bio's FY2025 proxy.
Committees
Research and Development
The full Q32 Bio compensation record
free company briefThis page is one person within Q32 Bio's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Q32 Bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.